- Policy
- Rapid support to develop COVID-19 vaccines & treatments
- by Kim, Jung-Ju Mar 29, 2020 11:19pm
- The government said it was moving rapidly to support R&D for the development of 'COVID-19' vaccine and exclusive treatment. Taeho Yoon, the director of Disinfection, the Central Disaster Management Headquarters (Public Health Policy Officer, the MOHW) today (25th) morning after the video conference about COVID-19/the central disaster and s
- Policy
- Gangnam Severance to test chloroquine preventing COVID-19
- by Lee, Tak-Sun Mar 29, 2020 11:18pm
- Gangnam Severance Hospital is to conduct a research-purpose clinical trial on malaria drug hydroxychloroquine to test its preventive effect, as it is currently used on patients with COVID-19. On Mar. 25, Korea’s Ministry of Food and Drug Safety (MFDS) approved the clinical trial protocol on a ‘Study on Hydroxychloroquine’s Post-exposur
- Policy
- “Lowest A7 price for latecommer PE-exempted RSA drug”
- by Lee, Hye-Kyung Mar 29, 2020 11:18pm
- When a first-in-class drug is listed with risk sharing agreement (RSA), a follow-on pharmacoeconomic evaluation (PE)-exempted drug would be reviewed for reimbursement feasibility with price higher than the lowest A7-adjusted price. And the revised review criteria added a phrase, ‘only referring to drugs with public health insurance reimburs
- Policy
- “NA should stop loosening new drug regulation”
- by Lee, Jeong-Hwan Mar 29, 2020 11:17pm
- Prior to the upcoming general election, health related civic groups are voicing out to the National Assembly (NA) about their disapproval on over-the-counter (OTC) drug sold outside of pharmacy and profit-making pharmacy. The groups urged the lawmakers to establish public pharmaceutical company, learning from COVID-19 outbreak, and sto
- Policy
- Saxenda's misuse and abuse are discussed
- by Lee, Tak-Sun Mar 26, 2020 06:12am
- The Ministry of Food and Drug Safety plans to release and disclose self-injection system safety management measures such as 'Saxenda', which has recently increased in sales volume as a weight management supplement. However, in the course of the discussion, there was still a large difference in opinion between doctors and pharmacists. Pati
- Policy
- Domestic drugs, access to the Chilean procurement market
- by Lee, Tak-Sun Mar 26, 2020 06:11am
- The KHIDI (Director Deok-cheol Kwon) announced that it has signed a Memorandum of Understanding (MOU) with Chile's Health Procurement Service (CENABAST, Valentin Diaz Gracia, Chief Executive Officer) and Korean companies to advance into public procurement of pharmaceuticals in Chile. The Chilean Health Procurement Authority (CENABAST) mana
- Policy
- Sanofi’s new laxative line-up DulcoSoft approved in Korea
- by Lee, Tak-Sun Mar 26, 2020 06:11am
- The world’s leading constipation relief Dulcolax maker Sanofi is expanding the brand line-up. The global company means to consolidate the leadership in the competitive Korean laxative market with new oral solution. On Mar. 23, Sanofi-Aventis Korea has received Ministry of Food and Drug Safety’s (MFDS) approval on DulcoSoft powder
- Policy
- Researchers from Korea start verifying COVID-19 treatments
- by Lee, Tak-Sun Mar 25, 2020 09:57am
- Treatments such as Hydroxychloroquine, used in COVID-19 infected patients, have entered clinical trials in earnest. Large hospitals, such as the AMC, have tried to verify safety and effectiveness through sponsor-investigator trials. Other hospitals besides the AMC have also been reported to apply for a clinical trial for Hydroxychloroquin
- Policy
- Advanced payment for COVID-19, expanded
- by Lee, Hye-Kyung Mar 25, 2020 06:02am
- care benefits, which were currently applied only to medical institutions in Daegu and Gyeongbuk. However, the support organizations are dedicated to the prevention of COVID-19 spread and treatment of patients and are limited to medical institutions, excluding pharmacies, The NHIS is expanding the nation's special cases of advance payment for
- Policy
- Eligibility standards on RSA change for better accessibility
- by Kim, Jung-Ju Mar 25, 2020 06:02am
- The risk sharing agreement (RSA) system implemented to enhance reimbursement access on an expensive drug would be amended and applied on follow-on drugs as well. To this date, multinational pharmaceutical companies and related industry have been strongly demanding for the change. They are now anticipating the change to resolve issues in
